Warner-Lambert
Executive Summary
Withdraws NDAs for thyroid hormones Euthroid and Proloid after "discovery of discrepancies between records kept by Warner-Lambert and records submitted to FDA," the agency said in a March 2 Federal Register notice. The discrepancies were discovered by FDA following a series of inspections of Warner-Lambert's Puerto Rico manufacturing facilities and record-keeping operations over the last two years ("The Pink Sheet" Dec. 14, 1992, p. 12).